Skip to main content
ME Therapeutics Holdings Inc. logo

ME Therapeutics Holdings Inc. — Investor Relations & Filings

Ticker · METX ISIN · CA5527671054 LEI · 984500T2I3C060D4F887 CSE Manufacturing
Open in API
Filings indexed 107 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country CA Canada
Listing CSE METX

About ME Therapeutics Holdings Inc.

https://metherapeutics.com/

ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company engaged in the discovery and development of novel therapeutics within the field of Immuno-Oncology. The company's core focus is on developing biological and small molecule drugs designed to target myeloid cells, a specific class of immune cells. These therapeutics are intended both to directly treat various cancers and to enhance the efficacy of existing Immuno-Oncology treatments, such as checkpoint inhibitors, particularly in cancers that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 90% confidence The document is a Venture Issuer Basic Certificate (Form 52-109FV2) certifying the interim filings for the period ended February 28, 2026 under Canadian NI 52-109. It is not the interim financial report itself, but a regulatory compliance certification accompanying those filings. No category specifically covers a certification letter, so it falls into the fallback “Regulatory Filings” category.
2026-04-21 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 80% confidence The document is a NI 52-109 Form 52-109FV2 "Certification of Interim Filings" by the CFO for a venture issuer. It is not the actual interim financial statements, MD&A, or an earnings release, nor is it a presentation, dividend notice, or other specific corporate event. It is a regulatory certification form required by Canadian securities rules, with no direct match among the specialized categories. Therefore it falls into the fallback category for miscellaneous regulatory filings (RNS).
2026-04-21 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Form 52-109FV2 venture issuer basic certificate certifying the interim financial report and MD&A for the period ended February 28, 2026. It is not itself the interim report (IR) nor an announcement of report publication (RPA), but a required regulatory certificate under NI 52-109. There is no specific category for certification forms, so it falls under General Regulatory Filings (RNS).
2026-04-21 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a CIRO Form 52-109FV2 “Venture Issuer Basic Certificate” certifying the interim filings (interim financial report and interim MD&A) for the period ended February 28, 2026. This is not the interim report itself (IR), nor an announcement of a report (RPA). It is a statutory certification filing under NI 52-109 with no dedicated category in our taxonomy. Therefore it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-21 English
Interim MD&A - English.pdf
Management Reports Classification · 93% confidence The document is titled “Management’s Discussion and Analysis for the three and six months ended February 28, 2026” and contains a management narrative covering results of operations, business strategy, liquidity, financing activities, forward-looking statements, and selected quarterly and annual data. It is an MD&A section accompanying an interim consolidated financial statement, which fits the definition of a Management Report (MDA) – a detailed management explanation of financial results and business trends for a period shorter than a year. It is not merely an announcement of publication, not a full annual report, and not another category such as earnings release or presentation. Therefore, it should be classified as MDA.
2026-04-21 English
Interim MD&A - English.pdf
Capital/Financing Update Classification · 75% confidence The document is a legal opinion letter from Torys LLP addressed to multiple Canadian securities commissions, providing consent for being named in the Bank’s Pricing Supplement dated April 21, 2026, to its short form base shelf prospectus dated September 9, 2024. This Pricing Supplement relates to TD Canada Bank’s issuance of Index-Linked Autocallable Coupon Notes (debt securities). The purpose of the letter is to facilitate the securities offering (a capital-raising event) by confirming that the firm’s legal opinions may be used in the prospectus and that there are no misrepresentations. This clearly pertains to a financing activity (the sale of debt notes) rather than a routine regulatory announcement, proxy, dividend, or management change. The most appropriate category for materials directly associated with a securities issuance is Capital/Financing Update (CAP).
2026-04-21 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.